Royalty Report: Drugs, Pharmaceuticals, Cancer – Collection: 25932


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Cancer
  • Therapeutic
  • Proteins
  • Medical
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 25932

License Grant
Our parent company, entered into a royalty Agreement with respect to interferon, transfer factor and products using interferon and transfer factor.
License Property
Interferon is the body’s first defense response to foreign substances such as viruses, interfering with the viral growth and replication processes. Interferons induce anti-viral, anti-tumor and immunomodulatory responses within the body. Clinical studies indicate that interferons may also inhibit malignant cell and tumor growth without affecting normal cell activity.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 159507

License Grant
The Company has a royalty agreement with Licensee, pursuant to which it is to receive a royalty on Licensees net sales of interferon and and transfer factor and products using interferon and transfer factor.  

The Board of Directors of Licensee and the Company have authorized amending the Royalty Agreement in consideration of the elimination of indebtedness of Licensee to the Company and of the promises and covenants set forth herein and for other good and valuable consideration, the parties agree to the following but not limited to; modifying the royalty section, extended the term, and rescinded a section.

License Property
Licensed Product shall mean Interferon, Transfer Factor and all products or any substance or group of substances which involve and include Interferon or Transfer Factor or any part of which product or any substance or group of substances includes Interferon or Transfer Factor.

Interferon shall mean and include a protein substance currently characterized as a viral neutralizing protein substance, whether produced naturally by lymphocytes, connective (fibroblast) tissue, including alpha, beta, and gamma interferon, and whether produced naturally or through a genetic engineering process.

Transfer Factor shall mean and include any lymphokine which exhibits specific biological activity for the protection of the body from viruses which is now recognized as mobilizing the natural immunological defense system of the body, whether the transfer factor is produced naturally from lymphokines or from other natural substances or whether produced through genetic engineering technology.

Field of Use
This agreement pertains the drug industry.

IPSCIO Record ID: 28006

License Grant
The agreement is with respect to interferon, transfer factor and products using interferon and transfer factor.

This amendment addresses compensation details.

Field of Use
The rights granted apply to the pharmaceutical market relating to the medical industry.

IPSCIO Record ID: 25899

License Grant
The Licensee has exercised an option to exclusively License a pending patent entitled, 'Method to Inhibit Proliferation and Growth of Metastases' from a University.
License Property
The resulting devices would inhibit tumor growth by reducing the presence of circulating growth factors without interfering with surgical wound healing or the recovery of tissue injured by radiation therapy. There is a significant unmet clinical need, as other drug agents may not be indicated for use in conjunction with surgical procedures or radiation treatment as they inhibit wound healing and tissue recovery.
Field of Use
The License provides a rapid development strategy for new cancer therapies by uniting drug agents that inhibit the spread of cancer-related metastases, with filtration techniques already proven in the Licensee's Hemopurifier(R).

The rights granted apply to the healthcare industry relating to reducing the presence of infectious viruses from human blood.

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.